TREATMENT OF HEMANGIOMAS WITH ALFA INTERFERON

阿尔法干扰素治疗血管瘤

• 批准号: 6441981
• 负责人: JUDAH FOLKMAN
• 金额: $ 2.88万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-12-01 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6441981
• 关键词: biomarker; blood chemistry; cardiovascular disorder chemotherapy; clinical research; clinical trial phase I; drug adverse effect; drug screening /evaluation; fibroblast growth factor; hemangioma; human subject; human therapy evaluation; immunotherapy; interferon alpha; serum; urinalysis

This study aim was to look at the efficacy of alfa interferon in the treatment of hemangiomas that are either destructive of tissue, disabling to the patient, or life-threatening. This includes determinig the side-effects and/or complications, if any, of alfa interferon therapy given over a period of time. The investigators will also determine whether urinary and/or serum levels of basic fibroblast growth factor (bFGF) can be used: 1) as a marker of disease activity; 2) as a marker of treatment efficacy; and 3) as a biochemical marker to distinguish between hemangiomas and other vascular anomalies.

这项研究的目的是研究阿尔法干扰素在血管瘤的治疗中的功效，这些血管瘤要么具有破坏性组织，因此致残患者或威胁生命。 这包括确定副作用和/或并发症（如果有的话），则包括一段时间内给予的阿尔法干扰素治疗。研究人员还将确定是否可以使用碱性成纤维细胞生长因子（BFGF）的尿和/或血清水平：1）作为疾病活动的标志； 2）作为治疗功效的标志； 3）作为生化标记，以区分血管瘤和其他血管异常。